[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Darya Chudova, identified as Chief Technology Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on a Form 4 filed for transactions dated 09/01/2025. The filing shows 316 restricted stock units deemed acquired at $0 (coded M) related to RSU vesting, and a reported disposition of 161 shares at $67.42. Following the transactions, the reporting person is shown as beneficially owning 81,610 shares after the acquisition line and 81,449 after the disposition line. The RSU award was originally granted on November 2, 2021 and fully vests on September 1, 2025, with vesting occurring in equal quarterly installments.

Positive

• RSUs vested: 316 restricted stock units recorded as acquired at $0, reflecting compensation realization
• Clear vesting schedule: RSU grant dated Nov 2, 2021 with full vesting on Sep 1, 2025, disclosed in the filing
• Compliance: Form 4 filed and signed by attorney-in-fact, meeting reporting requirements

Negative

• Disposition reported: 161 shares disposed at $67.42, reducing beneficial ownership from 81,610 to 81,449 shares

Insights

Financial Analyst

TL;DR: Routine executive equity vesting with a small reported disposition; not a material capital markets event.

The Form 4 documents standard equity compensation activity for an executive: 316 RSUs vesting (recorded as acquisition at $0) and a contemporaneous reported disposition of 161 shares at $67.42. Post-transaction beneficial ownership is shown around ~81.4k shares. This appears to reflect scheduled vesting and a minor sale or withholding, rather than a large open-market trade or change in control.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 reporting requirements for officer equity activity; vesting schedule is documented.

The filing identifies the reporting person as an officer (Chief Technology Officer) and provides the RSU grant history and vesting schedule (grant dated Nov 2, 2021, fully vesting Sep 1, 2025). The form is signed by an attorney-in-fact, indicating procedural compliance. The entries are specific and tied to the documented grant and vesting timeline.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudova Darya

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		M		316	A	$0	81,610	D
Common Stock	09/01/2025		F		161(1)	D	$67.42	81,449	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/01/2025		M			316	(2)	(1)	Common Stock	316	$0	0	D

Explanation of Responses:

1. Not applicable for Restricted Stock Units.

2. The restricted stock unit award was granted on November 2, 2021, of which 3,157 shares were outstanding on May 3, 2023, when the reporting person was elected as an officer. These shares vest in equal quarterly installments on the anniversary of September 1, 2022 and fully vest on September 1, 2025.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Darya Chudova	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Darya Chudova report on the Form 4 for GH?

The report shows 316 RSUs acquired at $0 (vesting) and a disposition of 161 shares at $67.42, both dated 09/01/2025.

How many Guardant Health (GH) shares does the filing show Darya Chudova beneficially owns after the transactions?

The filing shows beneficial ownership of 81,610 shares after the acquisition line and 81,449 shares after the disposition line.

When do the restricted stock units fully vest according to the Form 4?

The RSU award was granted on November 2, 2021 and is stated to fully vest on September 1, 2025 with equal quarterly installments.

What role does Darya Chudova hold at Guardant Health as indicated on the Form 4?

The Form 4 identifies Darya Chudova as an Officer, specifically the Chief Technology Officer.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by /s/ John G. Saia, as attorney-in-fact for Darya Chudova on 09/03/2025.